UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™

ATLANTA, Oct. 29, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the opening of applications for the second annual UCB U.S. Myasthenia Gravis Scholarship™, supporting individuals impacted by myasthenia gravis (MG) including patients, caregivers, and family members who are pursuing further education. To learn more the UCB Myasthenia Gravis Scholarship, or to apply online, visit www.UCBMGscholarship.com. In 2026, UCB will again award 15 scholarships. This year's application deadline is January 31, 2026. 

"The UCB U.S. Myasthenia Gravis Scholarship™ is dedicated to supporting people impacted by myasthenia gravis," said Kimberly Moran, PhD, MBA, SVP & Head, US Rare Diseases. "It's one of the many ways UCB is committed to empowering patients and caregivers—beyond medicine—through meaningful resources that help them thrive."

In the program's inaugural year, UCB helped recipients pursue diverse educational goals and gain new skills to further their career. Deanna C., inspired by her four-year-old daughter who is deaf, will use her scholarship to study American Sign Language at the University of New Hampshire. She said, "This scholarship is more than financial support. It's a symbol of the work that still needs to be done. Advocacy is no longer something I do. It's who I am."

Deric S. said, "This scholarship is actually going to take care of the rest of my Master's in Public Administration program, so that's a financial burden that I don't have to worry about. It's a really good feeling to know that you can have people to support you in your endeavors."

Visit the website to hear more from Deric S. about how the UCB Myasthenia Gravis Scholarship is helping to shape his future.

UCB Myasthenia Gravis Scholarship™ is a trademark of the UCB Group of Companies.
©2025 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-DA-2500837

For further information, contact UCB:

Daphne Teo
US Rare Disease Communications, UCB
[email protected]
T +1-770-880-7655

About UCB

UCB, Brussels, Belgium (www.ucb.com), is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9 000 people in approximately 40 countries, the company generated revenue of € 6.15 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

About the UCB Myasthenia Gravis Scholarship™

The UCB Myasthenia Gravis Scholarship offers educational scholarships to people living with myasthenia gravis and their immediate family members who are pursuing further education, whether they are continuing their education or aiming to gain new career skills. The scholarship can be used for an associate's, undergraduate, graduate degree, or specialty/trade school certificate. Scholarship requirements and limitations apply. For more information, please visit www.ucbmgscholarship.com.

Forward looking statements 

This press release contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this press release.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars and pandemics, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, you are cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this press release, and do not reflect any potential impacts from the evolving conflicts, wars, pandemics, as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation or duty to update any forward-looking statements in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

SOURCE UCB